Novavax, Inc. NASDAQ:NVAX

Novavax stock price today

$9.473
+1.19
+14.4%
Financial Health
0
1
2
3
4
5
6
7
8
9

Novavax stock price monthly change

-36.84%
month

Novavax stock price quarterly change

-36.84%
quarter

Novavax stock price yearly change

+67.61%
year

Novavax key metrics

Market Cap
1.37B
Enterprise value
N/A
P/E
-1.14
EV/Sales
-0.04
EV/EBITDA
0.13
Price/Sales
0.42
Price/Book
-1.11
PEG ratio
-0.01
EPS
-3.1
Revenue
831.68M
EBITDA
-345.59M
Income
-398.70M
Revenue Q/Q
15.94%
Revenue Y/Y
-35.49%
Profit margin
-39.43%
Oper. margin
-38.64%
Gross margin
45.9%
EBIT margin
-38.64%
EBITDA margin
-41.55%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Novavax stock price history

Novavax stock forecast

Novavax financial statements

Average Price Target
Last Year

$20.33

Potential upside: 114.65%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Novavax, Inc. (NASDAQ:NVAX): Profit margin
Jun 2023 424.42M 58.00M 13.67%
Sep 2023 22.06M -130.77M -592.71%
Dec 2023 291.34M -178.38M -61.23%
Mar 2024 93.85M -147.55M -157.21%
Novavax, Inc. (NASDAQ:NVAX): Debt to assets
Jun 2023 1685048000 2.43B 144.78%
Sep 2023 1657157000 2.33B 140.93%
Dec 2023 1855342000 2.57B 138.64%
Mar 2024 1353534000 2.22B 164.06%
Novavax, Inc. (NASDAQ:NVAX): Cash Flow
Jun 2023 -171.93M -7.77M 61.33M
Sep 2023 -39.65M -18.39M 197.12M
Dec 2023 -176.78M -9.07M 100.38M
Mar 2024 -83.55M -7.25M 5.88M

Novavax alternative data

Covid-19 Vaccine

Novavax, Inc. (NASDAQ:NVAX): Google Trends - Covid-19 Vaccine
26 Feb 2023 31000
5 Mar 2023 17000
12 Mar 2023 18000
19 Mar 2023 7000
26 Mar 2023 10000
2 Apr 2023 8000
9 Apr 2023 8000
16 Apr 2023 0000
23 Apr 2023 12000
30 Apr 2023 8000
7 May 2023 0000
14 May 2023 0000
21 May 2023 10000
28 May 2023 0000
4 Jun 2023 11000
11 Jun 2023 0000
18 Jun 2023 9000
25 Jun 2023 12000
2 Jul 2023 13000
9 Jul 2023 19000

Novavax

Novavax, Inc. (NASDAQ:NVAX): Google Trends - Novavax
26 Feb 2023 14
5 Mar 2023 12
12 Mar 2023 8
19 Mar 2023 8
26 Mar 2023 8
2 Apr 2023 5
9 Apr 2023 6
16 Apr 2023 6
23 Apr 2023 5
30 Apr 2023 4
7 May 2023 4
14 May 2023 4
21 May 2023 4
28 May 2023 4
4 Jun 2023 6
11 Jun 2023 6
18 Jun 2023 6
25 Jun 2023 9
2 Jul 2023 8
9 Jul 2023 8

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Novavax, Inc. (NASDAQ:NVAX): Job openings
Aug 2023 45
Sep 2023 59
Oct 2023 54
Nov 2023 43
Dec 2023 5
Jan 2024 6
Feb 2024 4
Apr 2024 14
May 2024 28
Jun 2024 15
Jul 2024 16
Dec 2024 4
Novavax, Inc. (NASDAQ:NVAX): Employee count
Aug 2023 1,992
Sep 2023 1,992
Oct 2023 1,992
Nov 2023 1,992
Dec 2023 1,992
Jan 2024 1,992
Feb 2024 1,992
Apr 2024 1,543
May 2024 1,543
Jun 2024 1,543
Jul 2024 1,543

Novavax other data

44.07% -0.75%
of NVAX is owned by hedge funds
32.78M -714.59K
shares is hold by hedge funds

Novavax, Inc. (NASDAQ:NVAX): Insider trades (number of shares)
Period Buy Sel
May 2024 0 47312
Jun 2024 0 28904
Transaction Date Insider Security Shares Price per share Total value Source
Option
CASEY MARK J officer: EVP, Chi.. Common Stock 41,900 N/A N/A
Option
CASEY MARK J officer: EVP, Chi.. Restricted Stock Units 41,900 N/A N/A
Option
TRIZZINO JOHN officer: EVP, CCO and CBO
Common Stock 655 N/A N/A
Option
TRIZZINO JOHN officer: EVP, CCO and CBO
Restricted Stock Units 655 N/A N/A
Option
KELLY JAMES PATRICK officer: EVP, CFO and Treasurer
Common Stock 2,367 $12.96 $30,676
Option
KELLY JAMES PATRICK officer: EVP, CFO and Treasurer
Restricted Stock Units 2,367 N/A N/A
Sale
YOUNG JAMES F director
Common Stock 7,500 $14.09 $105,675
Sale
YOUNG JAMES F director
Common Stock 6,393 $13.62 $87,073
Sale
YOUNG JAMES F director
Common Stock 1,107 $14.28 $15,808
Option
DUBOVSKY FILIP officer: President, R&D
Common Stock 12,500 $6.09 $76,125
Patent
Application
Filling date: 10 Aug 2021 Issue date: 7 Jul 2022
Grant
Filling date: 21 Nov 2017 Issue date: 21 Jun 2022
Application
Filling date: 25 Feb 2020 Issue date: 5 May 2022
Application
Filling date: 10 Jan 2022 Issue date: 28 Apr 2022
Grant
Filling date: 19 Mar 2019 Issue date: 22 Mar 2022
Application
Filling date: 24 Nov 2021 Issue date: 17 Mar 2022
Grant
Filling date: 18 Mar 2021 Issue date: 22 Feb 2022
Grant
Filling date: 20 Aug 2019 Issue date: 22 Feb 2022
Grant
Filling date: 15 Mar 2018 Issue date: 21 Sep 2021
Application
Filling date: 18 Mar 2021 Issue date: 29 Jul 2021
Insider Compensation
Mr. Stanley Charles Erck (1948) Pres, Chief Executive Officer & Director $1,260,000
Dr. Gregory M. Glenn (1954) Pres of R&D $857,420
Mr. John Joseph Trizzino B.S., M.B.A. (1960) Executive Vice President and Chief Bus. & Commercial Officer
$676,830
Mr. John A. Herrmann III (1966) Executive Vice President, Chief Legal Officer & Corporation Sec. $655,950
Tuesday, 24 December 2024
zacks.com
Friday, 13 December 2024
prnewswire.com
Thursday, 12 December 2024
zacks.com
Wednesday, 11 December 2024
zacks.com
Tuesday, 10 December 2024
zacks.com
prnewswire.com
Thursday, 5 December 2024
zacks.com
fool.com
Wednesday, 4 December 2024
reuters.com
prnewswire.com
Friday, 29 November 2024
zacks.com
Wednesday, 27 November 2024
accesswire.com
Tuesday, 26 November 2024
accesswire.com
investors.com
Friday, 22 November 2024
accesswire.com
Wednesday, 20 November 2024
accesswire.com
seekingalpha.com
Monday, 18 November 2024
prnewswire.com
zacks.com
Saturday, 16 November 2024
accesswire.com
accesswire.com
Friday, 15 November 2024
fastcompany.com
investopedia.com
prnewswire.com
Thursday, 14 November 2024
accesswire.com
accesswire.com
accesswire.com
Wednesday, 13 November 2024
zacks.com
prnewswire.com
seekingalpha.com
  • What's the price of Novavax stock today?

    One share of Novavax stock can currently be purchased for approximately $9.47.

  • When is Novavax's next earnings date?

    Unfortunately, Novavax's (NVAX) next earnings date is currently unknown.

  • Does Novavax pay dividends?

    No, Novavax does not pay dividends.

  • How much money does Novavax make?

    Novavax has a market capitalization of 1.37B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 38.48% to 983.71M US dollars.

  • What is Novavax's stock symbol?

    Novavax, Inc. is traded on the NASDAQ under the ticker symbol "NVAX".

  • What is Novavax's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Novavax?

    Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Novavax's key executives?

    Novavax's management team includes the following people:

    • Mr. Stanley Charles Erck Pres, Chief Executive Officer & Director(age: 77, pay: $1,260,000)
    • Dr. Gregory M. Glenn Pres of R&D(age: 71, pay: $857,420)
    • Mr. John Joseph Trizzino B.S., M.B.A. Executive Vice President and Chief Bus. & Commercial Officer(age: 65, pay: $676,830)
    • Mr. John A. Herrmann III Executive Vice President, Chief Legal Officer & Corporation Sec.(age: 59, pay: $655,950)
  • How many employees does Novavax have?

    As Jul 2024, Novavax employs 1,543 workers.

  • When Novavax went public?

    Novavax, Inc. is publicly traded company for more then 29 years since IPO on 5 Dec 1995.

  • What is Novavax's official website?

    The official website for Novavax is novavax.com.

  • Where are Novavax's headquarters?

    Novavax is headquartered at 21 Firstfield Road, Gaithersburg, MD.

  • How can i contact Novavax?

    Novavax's mailing address is 21 Firstfield Road, Gaithersburg, MD and company can be reached via phone at +240 2682000.

  • What is Novavax stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for Novavax in the last 12 months, the avarage price target is $20.33. The average price target represents a 114.65% change from the last price of $9.47.

Novavax company profile:

Novavax, Inc.

novavax.com
Exchange:

NASDAQ

Full time employees:

1,543

Industry:

Biotechnology

Sector:

Healthcare

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

21 Firstfield Road
Gaithersburg, MD 20878

CIK: 0001000694
ISIN: US6700024010
CUSIP: 670002401